BUSINESS

• Eisai to Offer 3 Rounds of Voluntary Retirement Program, to Cut 100 Jobs in March Next Year
  October 26, 2018

• Xofluza Bags US Approval: Shionogi
  October 26, 2018

• Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
  October 25, 2018

• Swiss API Manufacturer Bachem Establishes Japanese Subsidiary
  October 25, 2018

• GSK to Cover Cost of Rubella Testing and Vaccination for Employees
  October 25, 2018

• AVXS-101 Is Game Changer for SMA Treatment: Novartis Neuroscience Chief
  October 24, 2018

• Meiji Seika Pharma Files Safinamide for Parkinson’s Disease in Japan
  October 24, 2018

• Regenerative Medicine Product Market to Reach 225 Billion Yen in 2030: Fuji Keizai
  October 24, 2018

• Parexel CEO Sees Bright Future for Japan CRO Market
  October 23, 2018

• DS-8201 Shows Overall Response Rate of 15.8% in Patients with Colorectal Cancer in Japan-US PI Study: Daiichi Sankyo
  October 23, 2018

• Hisamitsu Begins Japan PII Study of Hyperhidrosis Treatment
  October 23, 2018

• Eisai, MSD Begin Joint Information Provisioning for Lenvima in Japan
  October 23, 2018

• Mitsubishi Tanabe Teams Up with Bioventure for Novel Antibody Drug Discovery Research in Autoimmune Diseases
  October 23, 2018

• Mundipharma Shooting for Japan Sales of US$500 Million in 10 Years: CEO
  October 22, 2018

• Daiichi Sankyo Begins 1st-in-Human Trial for AXL Inhibitor
  October 22, 2018

• JCR’s Hunter Syndrome Drug Grabs FDA’s Orphan Status
  October 22, 2018

• Eisai, Keio Univ. Identify Candidate Compound for Parkinson’s Disease Employing iPS Cells
  October 22, 2018

• Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
  October 19, 2018

• Takeda Earns Japan Clearance for Shire Acquisition
  October 19, 2018

• Asahi Kasei Obtains Patent License for iPS Cell-Derived Cartilage Regeneration Technology
  October 18, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 376
• 377
• 378
• 379
• 380
• 381
• 382
• 383
• 384
• …
• Next ›
• 最終 »